Reply
Mussarat N. Rahim, Michael A. Heneghan – 19 July 2019
Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis
Yoosoo Chang, Seungho Ryu, Yejin Kim, Yong Kyun Cho, Eunju Sung, Han‐Na Kim, Jiin Ahn, Hyun‐Suk Jung, Kyung Eun Yun, Seolhye Kim, Ki‐Chul Sung, Chong Il Sohn, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne – 19 July 2019
Interleukin‐32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance
Nassim Dali‐Youcef, Michel Vix, Federico Costantino, Houssein El‐Saghire, Benoit Lhermitte, Cosimo Callari, Jacopo D’Agostino, Silvana Perretta, Stefan Paveliu, Monica Gualtierotti, Edith Dumeny, Marine A. Oudot, Amélie Jaulin, Doulaye Dembélé, Mirjam B. Zeisel, Catherine Tomasetto, Thomas F. Baumert, Michel Doffoël – 19 July 2019 – Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder due to increased accumulation of fat in the liver and in many cases to enhanced inflammation.
Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population Cohorts
Fredrik Åberg, Pauli Puukka, Veikko Salomaa, Satu Männistö, Annamari Lundqvist, Liisa Valsta, Markus Perola, Martti Färkkilä, Antti Jula – 19 July 2019
Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure
Ben L. Da, Pallavi Surana, Devika Kapuria, Anusha Vittal, Elliot Levy, David E. Kleiner, Christopher Koh, Theo Heller – 18 July 2019
A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer
Mei‐Hsuan Lee, Yu‐Tang Gao, Yu‐Han Huang, Emma E. McGee, Tram Lam, Bingsheng Wang, Ming‐Chang Shen, Asif Rashid, Ruth M. Pfeiffer, Ann W. Hsing, Jill Koshiol – 18 July 2019
Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases
David W. Crabb, Gene Y. Im, Gyongyi Szabo, Jessica L. Mellinger, Michael R. Lucey – 17 July 2019
Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases
David W. Crabb, Gene Y. Im, Gyongyi Szabo, Jessica L. Mellinger, Michael R. Lucey – 17 July 2019
Letter to the Editor: The Porto‐Hepatic Spectrum of Cirrhotic Encephalopathy
Maria‐Angeles Aller, Jaime Arias, Javier Blanco‐Rivero – 17 July 2019
Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease
Ashley Cast, Meenasri Kumbaji, Amber D'Souza, Katherine Rodriguez, Anita Gupta, Rebekah Karns, Lubov Timchenko, Nikolai Timchenko – 17 July 2019 – Nonalcoholic fatty liver disease (NAFLD) involves development of hepatic steatosis, fibrosis, and steatohepatitis. Because hepatic steatosis appears first in NAFLD animal models, the current therapy development focuses on inhibition of hepatic steatosis, suggesting that further steps of NAFLD will be also inhibited. In this report, we show that the first event of NAFLD is liver proliferation, which drives fibrosis in NAFLD.